Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity

Blood

Volumn 121, Issue 18, 2013, Pages 3658-3665

  Reiners, Katrin S ^a   Topolar, Daniela ^a,e   Henke, Alexander ^a   Simhadri, Venkateswara R ^a,f   Kessler, Jörg ^a   Sauer, Maike ^a   Bessler, Martina ^a   Hansen, Hinrich P ^a   Tawadros, Samir ^a   Herling, Marco ^a   Krönke, Martin ^b,c   Hallek, Michael ^a,d   Von Strandmann, Elke Pogge ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c Cluster of Excellence Cellular Stress Responses in Aging Associated Diseases   (Germany)

^d University of Cologne   (Germany)

^e UNIVERSITY OF BONN   (Germany)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAG6 PROTEIN; BAT3 PROTEIN; CD16 ANTIGEN; CD56 ANTIGEN; HEAT SHOCK PROTEIN 70; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; PROTEIN P53; TUMOR PROTEIN; UNCLASSIFIED DRUG; BAG6 PROTEIN, HUMAN; CHAPERONE; FC RECEPTOR; LIGAND; NATURAL KILLER CELL RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CARCINOGENESIS; CELL STRESS; CELL TYPE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; EXOSOME; HUMAN; IMMUNE EVASION; IN VIVO STUDY; LEUKEMIA CELL; MCF 7 CELL LINE; NATURAL KILLER CELL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PLASMA FACTOR; PRIORITY JOURNAL; REPORTER GENE; SURFACE PROPERTY; TARGET CELL; TUMOR CELL; TUMOR CELL INOCULATION; TUMOR XENOGRAFT; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CELL STRAIN HEK293; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; GENE SILENCING; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SOLUBILITY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD56; CELLS, CULTURED; EXOSOMES; GENE KNOCKDOWN TECHNIQUES; HEK293 CELLS; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LIGANDS; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; MOLECULAR CHAPERONES; RECEPTORS, IGG; RECEPTORS, NATURAL KILLER CELL; SOLUBILITY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

MLCS; MLOWN;

EID: 84879716313     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-476606     Document Type: Article

References (48)

1. Riches JC, Ramsay AG, Gribben JG. Immune reconstitution in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2012;7(1):13-20.
2. Sanchez CJ, Le Treut T, Boehrer A, Knoblauch B, Imbert J, Olive D, Costello RT. Natural killer cells and malignant haemopathies: a model for the interaction of cancer with innate immunity. Cancer Immunol Immunother. 2011;60(1):1-13.
3. Waldhauer I, Steinle A. NK cells and cancer immunosurveillance. Oncogene. 2008;27(45):5932-5943.
4. Nausch N, Cerwenka A. NKG2D ligands in tumor immunity. Oncogene. 2008;27(45):5944-5958.
5. Lanier LL. Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008;9(5):495-502. (Pubitemid 351560518)
6. Salih HR, Holdenrieder S, Steinle A. Soluble NKG2D ligands: prevalence, release, and functional impact. Front Biosci. 2008;13:3448-3456. (Pubitemid 351594695)
7. Raulet DH, Gasser S, Gowen BG, Deng W, Jung H. Regulation of ligands for the NKG2D activating receptor [published online ahead of print January 3, 2013. Annu Rev Immunol.
8. Arnon TI, Achdout H, Levi O, et al. Inhibition of the NKp30 activating receptor by pp65 of human cytomegalovirus. Nat Immunol. 2005;6(5):515-523. (Pubitemid 41716765)
9. Mandelboim O, Lieberman N, Lev M, et al. Recognition of haemagglutinins on virus-infected cells by NKp46 activates lysis by human NK cells. Nature. 2001;409(6823):1055-1060. (Pubitemid 32204059)
10. Pogge von Strandmann E, Simhadri VR, von Tresckow B, et al. Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity. 2007;27(6):965-974. (Pubitemid 350251218)
11. Brandt CS, Baratin M, Yi EC, et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J Exp Med. 2009;206(7):1495-1503.
12. Rosental B, Brusilovsky M, Hadad U, et al. Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44. J Immunol. 2011;187(11):5693-5702.
13. Garg A, Barnes PF, Porgador A, et al. Vimentin expressed on Mycobacterium tuberculosis-infected human monocytes is involved in binding to the NKp46 receptor. J Immunol. 2006;177(9):6192-6198. (Pubitemid 44628837)
14. Chong WP, Zhou J, Law HK, Tu W, Lau YL. Natural killer cells become tolerogenic after interaction with apoptotic cells. Eur J Immunol. 2010;40(6):1718-1727.
15. Veuillen C, Aurran-Schleinitz T, Castellano R, et al. Primary B-CLL resistance to NK cell cytotoxicity can be overcome in vitro and in vivo by priming NK cells and monoclonal antibody therapy. J Clin Immunol. 2012;32(3):632-646.
16. Hilpert J, Grosse-Hovest L, Grünebach F, et al. Comprehensive analysis of NKG2D ligand expression and release in leukemia: implications for NKG2D-mediated NK cell responses. J Immunol. 2012;189(3):1360-1371.
17. Nückel H, Switala M, Sellmann L, et al. The prognostic significance of soluble NKG2D ligands in B-cell chronic lymphocytic leukemia. Leukemia. 2010;24(6):1152-1159.
18. Waldhauer I, Goehlsdorf D, Gieseke F, et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res. 2008;68(15):6368-6376.
19. Waldhauer I, Steinle A. Proteolytic release of soluble UL16-binding protein 2 from tumor cells. Cancer Res. 2006;66(5):2520-2526.
20. Costello RT, Knoblauch B, Sanchez C, Mercier D, Le Treut T, Sébahoun G. Expression of natural killer cell activating receptors in patients with chronic lymphocytic leukaemia. Immunology. 2012;135(2):151-157.
21. Walzer T, Dalod M, Robbins SH, Zitvogel L, Vivier E. Natural-killer cells and dendritic cells: "l'union fait la force". Blood. 2005;106(7):2252-2258. (Pubitemid 41510793)
22. Ferlazzo G, Tsang ML, Moretta L, Melioli G, Steinman RM, Münz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J Exp Med. 2002;195(3):343-351. (Pubitemid 34461492)
23. Vitale M, Della Chiesa M, Carlomagno S, Pende D, Aricò M, Moretta L, Moretta A. NK-dependent DC maturation is mediated by TNFalpha and IFNgamma released upon engagement of the NKp30 triggering receptor. Blood. 2005;106(2):566-571. (Pubitemid 40981252)
24. Grover A, Izzo AA. BAT3 regulates Mycobacterium tuberculosis protein ESAT-6-mediated apoptosis of macrophages. PLoS ONE. 2012;7(7):e40836.
25. Simhadri VR, Reiners KS, Hansen HP, et al. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS ONE. 2008;3(10):e3377.
26. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569-579. (Pubitemid 37328732)
27. Vlassov AV, Magdaleno S, Setterquist R, Conrad R. Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta. 2012;1820(7):940-948.
28. Yu X, Harris SL, Levine AJ. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 2006;66(9):4795-4801.
29. Yu X, Riley T, Levine AJ. The regulation of the endosomal compartment by p53 the tumor suppressor gene. FEBS J. 2009;276(8):2201-2212.
30. Lespagnol A, Duflaut D, Beekman C, et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ. 2008;15(11):1723-1733.
31. Krut O, Wiegmann K, Kashkar H, Yazdanpanah B, Krönke M. Novel tumor necrosis factor-responsive mammalian neutral sphingomyelinase-3 is a C-tail-anchored protein. J Biol Chem. 2006;281(19):13784-13793. (Pubitemid 43855294)
32. Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science. 2008;319(5867):1244- 1247. (Pubitemid 351323020)
33. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood. 2006;107(1):159-166. (Pubitemid 43053538)
34. Kim WJ, Okimoto RA, Purton LE, et al. Mutations in the neutral sphingomyelinase gene SMPD3 implicate the ceramide pathway in human leukemias. Blood. 2008;111(9):4716-4722.
35. Taylor DD, Gercel-Taylor C. Exosomes/microvesicles: mediators of cancer-associated immunosuppressive microenvironments. Semin Immunopathol. 2011;33(5):441-454.
36. Ge R, Tan E, Sharghi-Namini S, Asada HH. Exosomes in cancer microenvironment and beyond: have we overlooked these extracellular messengers? Cancer Microenviron. 2012;5(3):323-332.
37. Chalmin F, Ladoire S, Mignot G, et al. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120(2):457-471.
38. Gastpar R, Gehrmann M, Bausero MA, Asea A, Gross C, Schroeder JA, Multhoff G. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res. 2005;65(12):5238-5247. (Pubitemid 40827334)
39. Cho JA, Park H, Lim EH, Lee KW. Exosomes from breast cancer cells can convert adipose tissue-derived mesenchymal stem cells into myofibroblast-like cells. Int J Oncol. 2012;40(1):130-138.
40. Lee EY, Park KS, Yoon YJ, et al. Therapeutic effects of autologous tumor-derived nanovesicles on melanoma growth and metastasis. PLoS ONE. 2012;7(3):e33330.
41. Reinart N, Nguyen PH, Boucas J, et al. Delayed development of chronic lymphocytic leukemia in the absence of macrophage migration inhibitory factor. Blood. 2013;121(5):812-821.
42. Poggi A, Venturino C, Catellani S, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 2004;64(24):9172-9179. (Pubitemid 39665533)
43. Huergo-Zapico L, Gonzalez-Rodriguez AP, Contesti J, et al. Expression of ERp5 and GRP78 on the membrane of chronic lymphocytic leukemia cells: association with soluble MICA shedding. Cancer Immunol Immunother. 2012;61(8):1201-1210.
44. Champsaur M, Lanier LL. Effect of NKG2D ligand expression on host immune responses. Immunol Rev. 2010;235(1):267-285.
45. Reiners KS, Kessler J, Sauer M, et al. Rescue of impaired NK CELL ACTIVITY in Hodgkin Lymphoma with bispecific antibodies in vitro and in patients [published online ahead of print March 5, 2013]. Mol Ther. 2013.
46. Delahaye NF, Rusakiewicz S, Martins I, et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med. 2011;17(6):700-707.
47. North J, Bakhsh I, Marden C, et al. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: evidence of a two-stage process in resting NK cell activation. J Immunol. 2007;178(1):85-94. (Pubitemid 46033590)
48. Brenner CD, King S, Przewoznik M, et al. Requirements for control of B-cell lymphoma by NK cells. Eur J Immunol. 2010;40(2):494-504.